HalioDx

HalioDx is a specialized immuno-oncology diagnostic company that provides high-value prognostic and predictive tests to guide cancer treatment decisions. The company's flagship product, Immunoscore, is a standardized digital pathology assay that measures the host immune response at the tumor site by quantifying CD3+ and CD8+ T cells. This technology, based on the concept of the immune contexture, helps clinicians identify patients who are likely to benefit from specific therapies, particularly in colorectal cancer. HalioDx also offers a suite of assays for clinical trials and biopharmaceutical partnerships to support the development of immunotherapies. In 2021, the company was acquired by Veracyte to strengthen its global oncology diagnostic portfolio.